BioAge Labs (NASDAQ:BIOA) and Royalty Pharma (NASDAQ:RPRX) Critical ComparisonDefense World · 2 days ago
Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First TargetGlobeNewsWire · Oct 14, 2026
Bank of America Corp DE Buys 257,855 Shares of BioAge Labs, Inc. $BIOADefense World · Sep 28, 2026
BioAge Labs to Present at Upcoming Investor ConferencesGlobeNewsWire · Sep 25, 2026
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 16, 2026
BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha · Sep 9, 2026BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.61 | -$0.58 | Beat |
| May 8, 2026 | -$0.64 | -$0.52 | Beat |
| Mar 24, 2026 | -$0.83 | -$0.72 | Beat |
| Nov 6, 2025 | -$0.67 | -$0.56 | Beat |
| Aug 6, 2025 | -$0.56 | -$0.60 | Miss |
| May 6, 2025 | -$0.52 | -$0.36 | Beat |